Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant

Rhea-AI Filing Summary

Fate Therapeutics director William H. Rastetter received a grant of stock options covering 87,900 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036.

The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards to non-employee directors on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service on the Board. Following this grant, he holds 87,900 options according to this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider RASTETTER WILLIAM H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 shares (Direct, null)

Footnotes (1)

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Key Figures

Options granted: 87,900 options Exercise price: $2.06 per share Expiration date: June 12, 2036 +2 more

5 metrics

Options granted 87,900 options Stock Option (Right to Buy) grant to director

Exercise price $2.06 per share Conversion or exercise price of options

Expiration date June 12, 2036 Option expiration for director grant

Shares following transaction 87,900 options Total derivative holdings after grant in this filing

Vesting date June 12, 2027 or 2027 annual meeting Earlier of two dates, subject to continued Board service

Key Terms

Stock Option (Right to Buy), Amended and Restated Non-Employee Director Compensation Policy, Annual Meeting of Stockholders, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for the reported transaction"

Amended and Restated Non-Employee Director Compensation Policy financial

"grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

Annual Meeting of Stockholders financial

"annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders"

vesting financial

"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RASTETTER WILLIAM H

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		87,900		(2)	06/12/2036	Common Stock	87,900	$0	87,900	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Fate Therapeutics (FATE) director William H. Rastetter report in this Form 4?

He reported receiving a grant of stock options for 87,900 shares of Fate Therapeutics Common Stock. The options were awarded under the company’s Non-Employee Director Compensation Policy and represent equity-based compensation for his Board service.

What are the key terms of William H. Rastetter’s new Fate Therapeutics stock options?

The options cover 87,900 shares of Common Stock at an exercise price of $2.06 per share. They expire on June 12, 2036, providing a long-dated incentive aligned with the company’s future performance and his ongoing Board service.

When do William H. Rastetter’s Fate Therapeutics options vest?

The options vest and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is conditioned on his continued service on the company’s Board of Directors.

How many Fate Therapeutics options does William H. Rastetter hold after this transaction?

After this grant, he holds 87,900 stock options according to the Form 4. All of these options relate to Fate Therapeutics Common Stock and were acquired as a compensation award rather than through an open-market purchase.

Was William H. Rastetter’s Fate Therapeutics option grant part of a standard director compensation program?

Yes. The footnotes state the grant was made under Fate Therapeutics’ Amended and Restated Non-Employee Director Compensation Policy. This policy provides annual equity grants to non-employee directors on the date of the company’s Annual Meeting of Stockholders.